Bone Marrow Transplant For Thalassemia

Among 1,469 children transplanted for thalassemia major in Turkey, 92.3 percent were alive five years later and 82.1 percent were free of thalassemia. Results were best before the age of seven.

Those figures come from 25 pediatric centers reporting every first transplant between 1988 and 2020 (Yesilipek and colleagues, Bone Marrow Transplantation, 2022). The European registry tells the same story. Of 1,493 patients transplanted between 2000 and 2010, 88 percent were alive at two years and 81 percent were cured, and with a matched brother or sister as donor the figures rose to 91 and 83 percent (Baronciani and colleagues, Bone Marrow Transplantation, 2016). A bone marrow transplant for thalassemia replaces the stem cells that make faulty red cells with healthy ones from a donor, and it ends the need for transfusions for life. It also carries a real risk, which falls when the child is young and iron has been well controlled. This page explains who is suited to it, how donors are found, what the months of treatment involve, and how families from abroad can plan it with Biruni Hospital in Istanbul.

A cure, with conditions

Children with thalassemia major cannot make enough normal hemoglobin. They depend on a blood transfusion every three or four weeks and on daily medicine to remove the iron that transfusions leave behind. With good care that routine now carries people into their fifties and beyond. It never ends, though, and iron slowly harms the heart, the liver and the glands.

More than 90 percent of patients now survive the transplant, and disease-free survival is around 80 percent, according to an international expert panel that reviewed worldwide experience in 2014.

That panel also set out who should be offered a transplant. Its main points follow.

• A child with transfusion-dependent thalassemia and a tissue-matched brother or sister should be offered a transplant early, before iron has caused damage.
• A well-matched unrelated donor is an acceptable alternative when no sibling matches.
• Transplants from half-matched relatives belong in experienced centers.
• Adolescents and adults can be transplanted, with higher risk, after careful assessment of heart and liver.
• Families deserve a plain comparison with lifelong transfusion and chelation, which remains a sound choice.

Why early

Every year of transfusion adds iron, and iron in the liver and heart is what makes a transplant dangerous. A child transplanted at four has a clean liver, a heart that has never met iron, glands that will carry her through puberty without help, and a long life in which to enjoy the result. In the Turkish series, outcomes were significantly better under the age of seven, after 2010, and in centers that had performed more than 100 thalassemia transplants.

Finding a donor

Tissue typing

A blood sample or cheek swab from the child, both parents and every full brother and sister is tested for HLA, the proteins by which the immune system tells self from other. Each sibling has a one in four chance. A sibling who carries the thalassemia trait, as many do, is a perfectly good donor.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Donating marrow carries very little risk for a child. Doctors take it from the hip bones with a needle under a short general anesthetic, the donor goes home the next day with a sore back for a few days, and the marrow regrows within weeks.

Risk before transplant

Three questions about iron

Doctors in Pesaro, Italy, who pioneered this treatment in the 1980s, found that three findings predicted how a child would fare. Transplant teams still use their classification.

Class 1 means none of the three is present, class 2 means one or two, and class 3 means all three. Class 1 children do best, and preparation before transplant aims to move a child down a class.

The transplant, stage by stage

From admission to going home takes four to six weeks. The whole process, from the first chelation push to stopping immune-suppressing medicine, takes a year.

What happens when

Below is a typical plan. Your team will give you dates.

What can go wrong

Parents should hear the risks stated plainly before they decide.

1. Graft rejection. The child's own marrow returns and with it thalassemia. In the two registries roughly one child in ten returned to transfusion, more often in class 3 and with mismatched donors. Transfusions resume, and a second transplant is sometimes possible.
2. Graft-versus-host disease. Donor immune cells attack skin, gut or liver. Mild forms are common and settle with treatment. In the Turkish series chronic disease affected 8.3 percent of survivors and persisted at last follow-up in 2.2 percent.
3. Infection. Bacterial, viral and fungal infections during the months of low immunity, prevented and treated with a range of medicines.
4. Liver complications. A blockage of small liver veins called veno-occlusive disease is more frequent in iron-loaded livers. A preventive medicine is given to children at risk.
5. Death from the procedure. By the time of analysis, 8 to 12 percent of patients in the two registries had died. The risk is lower in young class 1 children with sibling donors and higher in adults.

Mixed chimerism

Sometimes donor and patient cells settle into a lasting partnership. When a fifth or more of the marrow is donor, the child needs no transfusions as a rule, and in the Turkish series such children had significantly less chronic graft-versus-host disease. Doctors watch the proportion. They adjust immune suppression to protect it.

What the registries show

Europe

Europe's registry covered 1,493 consecutive patients in many countries. Ninety-one percent had not yet turned 18, and 1,061 had a matched sibling donor. Country made no difference. The authors found a threshold near 14 years of age. Below it, overall survival ran from 90 to 96 percent and thalassemia-free survival from 83 to 93 percent. Above it, both fell.

National series, 1,469 patients, median age seven, median follow-up 62 months. Overall survival 92.3 percent, thalassemia-free survival 82.1 percent, and survival free of both thalassemia and chronic graft-versus-host disease 80.8 percent.

Reading the numbers

The gap between survival and cure, some ten percentage points, consists mostly of children whose graft was rejected and who returned to transfusion. Those children live on, no worse off than before apart from the months spent. The remaining gap, between survival and 100, is the price of the attempt, and it is paid early. That is hard. A family weighing it should set it against the slow, late risks of iron over four or five decades, and against the fact that modern chelation has made those risks much smaller than they were when transplantation began.

Life after transplant

The first year

Doctors taper immune-suppressing medicine from six months and stop it around a year if no graft-versus-host disease has appeared. School resumes after six to nine months. Vaccines start again from the beginning.

Other treatments on the horizon

Gene therapy, in which the patient's own stem cells are corrected and returned after similar chemotherapy, has been approved in some countries for patients aged twelve and over. It removes the need for a donor and the risk of graft-versus-host disease. The cost runs extremely high, access is narrow, and follow-up is still short, so nobody can yet say whether the corrected cells will keep working for fifty years as a donor graft has been shown to do. A drug that reduces transfusion need in some adults also exists. For a young child with a matched sibling, transplant remains the established cure, with forty years of follow-up behind it and adults now in middle age who were transplanted as toddlers and have long since stopped thinking of themselves as patients.

Coming from abroad

Families start by sending the diagnosis, transfusion and chelation history, recent ferritin, liver and heart iron results where available, and any tissue typing already done. The review costs nothing. If no typing exists, the reply explains how samples from parents and siblings can be tested. When a donor is confirmed, the written plan sets out preparation, dates and the length of stay. Expect to live in Istanbul for three to four months, which covers the admission and the period of close follow-up to about day 100, and plan for the donor sibling to be present for the first two weeks. One parent stays in the hospital room on the companion bed and the rest of the family in accommodation nearby. Doctors consider children fit to fly when blood counts are stable without transfusion, immune suppression is at a steady dose and no infection or active graft-versus-host disease is present, and the team writes a detailed handover for the hematologist who will follow your child once you are back home.

One coordinator from the international patients office handles arrangements from the first message through discharge and answers the same WhatsApp number afterward. The office works in English, Arabic, French, Russian, Serbian, Romanian and Spanish and books interpreters for other languages. It arranges the visa invitation letter for the whole family, airport transfers, daily transport and accommodation. The kitchen prepares halal, vegetarian and diabetic meals. A prayer room is on site, and a request for a female physician is met wherever the rota allows.

Cost

The estimate follows the file review. Hospitals in this market price a sibling transplant as a package that covers donor workup, marrow harvest, conditioning, the admission and a defined follow-up period, and they itemize unrelated donor search fees, extra nights and treatment of complications.

Confirm what your package includes. Several governments and charities fund thalassemia transplants abroad, and the coordinator can supply the documents they ask for.